CT-0508
Phase 1- Indications
- Solid tumors
Company intelligence / Profile preview
Sesen Bio
Cambridge, Massachusetts, United Statessesenbio.com ↗
- Ownership
- Private
- Employees
- ~50
- Development stage
- Phase 1
01
Overview
In July 2022, Sesen Bio voluntarily paused further development of Vicineum in the US after reassessment and discussions with the FDA, which would have required an additional Phase III clinical trial[6]
- Therapeutic areas
- Oncology
- Modalities
- Fusion protein medicinesAntibody-drug conjugates (ADCs)
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Sesen Bio.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Sesen Bio.